中文摘要：

目的：探究吡格列酮和二甲双胍对初诊2型糖尿病患者肠源性内毒素水平的影响。方法：选取初诊2型糖尿病患者105例,随机分为吡格列酮治疗组（52例）和二甲双胍治疗组（53例）,以同期性别、年龄匹配的健康体检者42例作为对照组,治疗12周之后比较两组治疗前后肠源性内毒素及相关生化指标的变化情况。结果：治疗前,两治疗组的肠源性内毒素水平均显著高于对照组（P〈0.05）;吡格列酮治疗后,患者肠源性内毒素和hs-CRP水平均下降较为明显（P〈0.01）;而二甲双胍治疗后,仅hs-CRP水平显著下降,差异具有统计学意义（P〈0.05）,而肠源性内毒素下降不明显（P〉0.05）;但两种药物治疗后,肠源性内毒素水平仍高于对照组（P〈0.01）。结论：吡格列酮可以降低初诊2型糖尿病患者的肠源性内毒素水平,而二甲双胍对肠源性内毒素的下降作用不明显。

英文摘要：

Objective： To study the effect of pioglitazone and metformin on intestinal endotoxemia levels in patients with newly diagnosed type 2 diabetes. Methods： 105 patients with newly diagnosed type 2 diabetic were randomly divided into the pioglitazone treatment group（52 cases） and metformin treatment group（53 cases）, 42 sex, age-matched healthy people were selected as Control in the same period. The changes of intestinal endotoxemia and biochemical parameters levels after 12 weeks＇ treatment were compared. Results：The intestinal endotoxemia lever were higher in both pioglitazone and metformin treatment groups before treatment than that of the control group（P〈0.05）. When pioglitazone was used, toxins, hs-CRP levels in the intestinal were decreased more significantly（P〈0.01）, only hs-CRP decrease was statistically significant when metformin used（P〈0.05）, no significant decline in intestinal endotoxemi. Toxin level was still higher than those in the intestinal after the 2 drugs treatment（P〈0.01）. Conclusions： Pioglitazone could reduce the intestinal endotoxemia level of patients with newly diagnosed type 2 diabetes, while metformin hadn＇t obvious effect on the intestinal endotoxemia level.